XOMA Royalty (XOMA) Invested Capital (2011 - 2026)
XOMA Royalty (XOMA) reported Invested Capital of $14.0 million for Q1 2026, up 2.31% on a YoY basis from $13.7 million in Q1 2025, and up 11.87% sequentially from $12.5 million in Q4 2025.
XOMA Royalty (XOMA) Invested Capital (2011 - 2026) Analysis & Trends
XOMA Royalty (XOMA) has 15 years of Invested Capital data on file, last reported at $14.0 million in Q1 2026.
- For the quarter ending Q1 2026, Invested Capital rose 2.31% year-over-year to $14.0 million; the trailing twelve-month figure through Mar 2026 stood at $38.2 million (down 5.96% YoY), and the FY2025 full-year result was $12.5 million, up 9.94% from the prior year.
- Invested Capital improved to $14.0 million in Q1 2026, from $12.5 million in the prior quarter.
- In the past five years, Invested Capital ranged from a high of $14.0 million in Q1 2026 to a low of $5.5 million in Q4 2023.
- A 4-year average of $10.1 million and a median of $11.4 million in 2024 frame the typical range for Invested Capital.
- Across the five-year window, Invested Capital jumped 122.93% in 2025 and increased 2.31% in 2026, its largest moves.
- Tracing XOMA's Invested Capital over 4 years: stood at $5.5 million in 2023, then jumped by 105.56% to $11.4 million in 2024, then climbed by 9.94% to $12.5 million in 2025, then rose by 11.87% to $14.0 million in 2026.
- Business Quant data shows XOMA's Invested Capital at $14.0 million in Q1 2026, $12.5 million in Q4 2025, and $11.7 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Invested Cap. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | - |
| 2 | Nanobiotix | 1,913.50 Bn | 1,913.44 Bn | - | 110.96 Mn |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 473.74 Bn | 468.95 Bn | 1.35 Bn | 116.14 Mn |
| 5 | Vertex Pharmaceuticals | 122.07 Bn | 114.82 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.00 Bn | 61.24 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.96 Bn | 50.77 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | - |
| 10 | XOMA Royalty | 478.42 Mn | 412.34 Mn | - | 14.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.01 Mn |
| Dec 31, 2025 | 12.53 Mn |
| Jun 30, 2025 | 11.67 Mn |
| Mar 31, 2025 | 13.70 Mn |
| Dec 31, 2024 | 11.39 Mn |
| Sep 30, 2024 | 9.83 Mn |
| Jun 30, 2024 | 5.72 Mn |
| Mar 31, 2024 | 6.14 Mn |
| Dec 31, 2023 | 5.54 Mn |
| Mar 31, 2021 | 7.20 Mn |
| Dec 31, 2020 | 8.09 Mn |
| Sep 30, 2020 | 8.96 Mn |
| Jun 30, 2020 | 7.60 Mn |
| Mar 31, 2020 | 6.39 Mn |
| Dec 31, 2019 | 5.18 Mn |
| Sep 30, 2019 | 3.98 Mn |
| Jun 30, 2019 | 2.68 Mn |
| Mar 31, 2019 | 1.73 Mn |
| Dec 31, 2018 | 789,000.00 |
| Jun 30, 2017 | 13.54 Mn |